HomeNews & TopicsResearchCancer diagnoses dropped sharply in Alberta during COVID-19 response

Cancer diagnoses dropped sharply in Alberta during COVID-19 response

Published on

Pandemic restrictions corresponded with a significant drop in diagnoses of breast, colorectal and prostate cancers as well as melanoma, according to a new Alberta study published in CMAJ (Canadian Medical Association Journal).

“The sweeping and unprecedented measures enacted at the beginning of the COVID-19 pandemic in Alberta had an inevitable impact on cancer care,” writes Dr. Darren Brenner, an epidemiologist in Calgary, Alberta, and associate professor at the University of Calgary’s Cumming School of Medicine, with coauthors. “Even though treatment and urgent surgeries for cancers were prioritized when other procedures were delayed or cancelled, preventive and diagnostic services were greatly reduced.”

The study compared survival rates for 3 groups of patients diagnosed between (1) Jan. 16, 2018, and Mar. 15, 2019; (2) Mar. 16, 2019, and Mar. 15, 2020; and (3) Mar. 16 and Dec. 15, 2020. The researchers divided the third period into a “state of emergency” (SOE) phase (Mar. 16 to June 15, 2020) and post-SOE phase (June 16 to Dec. 15, 2020).

Researchers saw large reductions in the number of new diagnoses for some cancer types during the SOE period, with a drop of 43% (melanoma), 36% (colorectal and prostate) and 33% (breast). In the post-SOE phase, diagnoses increased 9%, 8% and 10% per month, respectively. Other cancers, such as bladder, kidney, lung and cervical, did not show decreases in diagnoses during that period.

“Our findings that early-stage breast and colorectal cancer had the largest decrease in diagnoses suggest that a reduction in screening services during the first wave of pandemic-related restrictions in Alberta resulted in asymptomatic individuals receiving a diagnosis later than they would have otherwise,” write the authors. “These results highlight the importance of screening services in reducing late-stage cancer diagnoses.”

Patients with colorectal cancer and non-Hodgkin lymphoma diagnosed during the pandemic period in 2020 had poorer 1-year survival than those diagnosed in 2018.

By December 2020, the rate of diagnoses had returned to a level more in line with pre-SOE levels.

The findings are consistent with studies from the United Kingdom, United States, the Netherlands, Germany, Japan and other parts of Canada. In Ontario, there was a 34% drop in new cancer diagnoses in April 2020, and Manitoba had a 23% reduction in the same period. An estimated 15% reduction in Quebec occurred in the first year of the pandemic.

Cancer care must become more efficient and increase capacity to reduce long-term effects of the pandemic on cancer outcomes, the authors conclude.

“Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta” is published June 12, 2023.

Latest articles

New research links brain region to linguistic ability

The cerebellum, typically associated with movement, may also play a key role in reading...

Making Clinical Research a Care Option: How Digital Infrastructure is Expanding Access to Clinical Trials in Canada

Across Canada, there is growing recognition that clinical research should not be viewed as...

Privacy-First AI: How Federated Learning Is Transforming Canadian Cancer Research

Imagine training an AI model on patient data from hospitals in Vancouver, Toronto, and...

People living with Parkinson’s face long wait times, inconsistent care across Canada

Parkinson Canada launches Limitless Parkinson’s Care campaign for this Parkinson’s Awareness Month. Accessing Parkinson’s care...

More like this

This Canadian startup is decoding the health data revealed in our eyes

If you’ve had a fluorescein angiography (FA), chances are you remember it. The procedure...

A new home for Canada’s largest Cancer Research Tumour Bank

Decades of cancer research — and thousands of patient tumour samples — now have...

Equity-focused study on immigrant kidney disease risk

HN Summary • A new SHN-led study published in BMJ Open reveals significant disparities in...

Shorter duration of antimicrobial therapy in common infections

HN Summary • Growing evidence shows that shorter courses of antibiotics are just as effective...

Global clinical trial exploring potential treatment for sickle cell disease

HN Summary • SHN is leading a global clinical trial testing tebapivat, an investigational oral...

Lithium study yields insights in the fight against HIV

Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway,...